Who are DAS181's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Raxtozinameran 6 months to 4 years of age.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/das181.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DAS181 — Competitive Intelligence Brief

DAS181 (DAS181) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant fusion protein; viral entry inhibitor. Area: Infectious Disease; Virology.

phase 3 Recombinant fusion protein; viral entry inhibitor DPP4 (dipeptidyl peptidase 4) receptor Infectious Disease; Virology Small molecule Live · refreshed every 30 min

Target snapshot

DAS181 (DAS181) — Ansun Biopharma, Inc.. DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DAS181 TARGET	DAS181	Ansun Biopharma, Inc.	phase 3	Recombinant fusion protein; viral entry inhibitor	DPP4 (dipeptidyl peptidase 4) receptor
Raxtozinameran 6 months to 4 years of age	raxtozinameran-6-months-to-4-years-of-age	Pfizer	marketed	viral entry inhibitor	SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant fusion protein; viral entry inhibitor class)

Ansun Biopharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAS181 — Competitive Intelligence Brief. https://druglandscape.com/ci/das181. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab